Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

Makoto Hosono; Masako N. Hosono; Françoise Kraeber-Bodéré; Anne Devys; Philippe Thédrez; Maryse Fiche; Emmanuel Gautherot; Jacques Barbet; Jean-François Chatal

Research ArticleNuclear Oncology

Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

Makoto Hosono, Masako N. Hosono, Françoise Kraeber-Bodéré, Anne Devys, Philippe Thédrez, Maryse Fiche, Emmanuel Gautherot, Jacques Barbet and Jean-François Chatal

Journal of Nuclear Medicine September 1998, 39 (9) 1608-1613;

Makoto Hosono

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Masako N. Hosono

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Françoise Kraeber-Bodéré

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anne Devys

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Philippe Thédrez

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maryse Fiche

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Emmanuel Gautherot

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacques Barbet

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean-François Chatal

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Info & Metrics
PDF

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 39, Issue 9

September 1, 1998

Table of Contents
Table of Contents (PDF)
Index by author
Advertising (PDF)
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

Makoto Hosono, Masako N. Hosono, Françoise Kraeber-Bodéré, Anne Devys, Philippe Thédrez, Maryse Fiche, Emmanuel Gautherot, Jacques Barbet, Jean-François Chatal

Journal of Nuclear Medicine Sep 1998, 39 (9) 1608-1613;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

Makoto Hosono, Masako N. Hosono, Françoise Kraeber-Bodéré, Anne Devys, Philippe Thédrez, Maryse Fiche, Emmanuel Gautherot, Jacques Barbet, Jean-François Chatal

Journal of Nuclear Medicine Sep 1998, 39 (9) 1608-1613;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

Pretargeting: A Path Forward for Radioimmunotherapy
Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft

Google Scholar

Main menu

User menu

Search

Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles